Affordable Access

Access to the full text

[Resistance to anti-angiogenic therapy: a clinical and scientific current issue].

Authors
  • Gu, Yuchen
  • Lu, He
  • Boisson-Vidal, Catherine
  • Li, Hong
  • Bousquet, Guilhem
  • Anne Janin
  • Di Benedetto, Mélanie
Type
Published Article
Journal
médecine/sciences
Publisher
EDP Sciences
Publication Date
Apr 05, 2016
Volume
32
Issue
4
Pages
370–377
Identifiers
DOI: 10.1051/medsci/20163204015
PMID: 27137694
Source
USPC - SET - SVS
License
Green

Abstract

Although the use of anti-angiogenic agents has been considered a promising strategy to block tumor growth and improve the bioavailability of drugs into the tumor, the use of most of them in clinical trials is limited. The development of resistance to some anti-angiogenic agents and their high toxicity are currently under investigations. However, the approach is still valid since this therapeutic tool has lengthened survival of patients with colon, breast, kidney, lungs and liver cancers. The identification of biomarkers in response to this family of drugs is an important area of investigation.

Report this publication

Statistics

Seen <100 times